Logo

ABT

Abbott Laboratories

ABT

Abbott Laboratories • NYSE
$128.90 ▲ 0.28% (+0.36)
Market Cap $224.36 B
52w High $141.23
52w Low $110.86
Dividend Yield 2.36%
P/E 16.17
Volume 2.51M
Outstanding Shares 1.74B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $11.369B ▲ $4.308B ▲ $1.644B ▼ 14.46% ▼ $0.94 ▼ $3.015B ▼
Q2-2025 $11.142B ▲ $4.236B ▲ $1.779B ▲ 15.967% ▲ $1.02 ▲ $3.048B ▲
Q1-2025 $10.358B ▼ $3.756B ▲ $1.325B ▼ 12.792% ▼ $0.758 ▼ $2.668B ▼
Q4-2024 $10.974B ▲ $3.608B $9.229B ▲ 84.099% ▲ $5.33 ▲ $2.989B ▲
Q3-2024 $10.635B $3.608B $1.646B 15.477% $0.95 $2.907B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.733B ▲ $84.181B ▲ $32.917B ▼ $50.954B ▲
Q2-2025 $7.282B ▲ $83.999B ▲ $33.17B ▲ $50.565B ▲
Q1-2025 $6.844B ▼ $81.448B ▲ $32.384B ▼ $48.811B ▲
Q4-2024 $7.967B ▲ $81.414B ▲ $33.513B ▼ $47.664B ▲
Q3-2024 $7.788B $74.356B $34.328B $39.796B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.644B ▼ $2.787B ▲ $-457M ▲ $-1.76B ▼ $560M ▲ $2.291B ▲
Q2-2025 $1.779B ▲ $2.047B ▲ $-582M ▼ $-1.097B ▲ $419M ▲ $1.545B ▲
Q1-2025 $1.325B ▼ $1.417B ▼ $-470M ▲ $-2.055B ▼ $-1.084B ▼ $933M ▼
Q4-2024 $9.229B ▲ $2.868B ▲ $-866M ▼ $-1.861B ▼ $58M ▼ $2.148B ▼
Q3-2024 $1.646B $2.705B $-594M $-1.576B $571M $2.149B

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Diagnostic Products
Diagnostic Products
 $2.52Bn ▲$2.05Bn ▼$5.90Bn ▲$6.00Bn ▲
Established Pharmaceutical Products
Established Pharmaceutical Products
 $1.27Bn ▲$1.26Bn ▼$1.38Bn ▲$1.51Bn ▲
Medical Devices
Medical Devices
 $5.05Bn ▲$4.89Bn ▼$5.37Bn ▲$5.45Bn ▲
Nutritional Products
Nutritional Products
 $2.13Bn ▲$2.15Bn ▲$2.21Bn ▲$2.15Bn ▼

Five-Year Company Overview

Income Statement

Income Statement Abbott’s sales have been fairly steady over the past few years, with a spike during the pandemic from testing and then a gentle step down as that temporary boost faded. More recently, revenue has begun to grow again, suggesting the core businesses are picking up the slack from lower COVID-related sales. Profitability has stayed healthy, with solid gross and operating margins, although slightly lower than at the pandemic peak. The most recent year shows an unusually strong jump in reported net income and earnings per share, which likely reflects one‑off items rather than a permanent step‑change. Overall, the income statement points to a mature, diversified company with resilient earnings, but with some noise from pandemic and non‑recurring effects.

Balance Sheet

Balance Sheet Abbott’s balance sheet looks robust and has been improving. Total assets have edged up over time, while cash levels are comfortably high for a company of its size. Debt has been slowly coming down, which reduces financial risk and interest burden. Shareholders’ equity has risen meaningfully, showing that the business is building value on its balance sheet rather than just treading water. The overall picture is one of a large, well-capitalized company with a moderate and declining reliance on borrowing.

Cash Flow

Cash Flow Cash generation is a clear strength. Abbott regularly produces operating cash flow that comfortably exceeds its investment needs. After funding capital expenditures, there is still substantial free cash flow left over, and this has been consistently positive across the period shown. Investment spending has been steady rather than aggressive, suggesting disciplined capital allocation rather than big, risky bets. The strong conversion of earnings into cash supports financial flexibility for research, acquisitions, and returns to shareholders, while also providing a cushion during industry or macroeconomic slowdowns.

Competitive Edge

Competitive Edge Abbott holds a strong competitive position built on diversification and scale. It operates across medical devices, diagnostics, nutrition, and established pharmaceuticals, which spreads risk and smooths results when one area is under pressure. In several niches—such as continuous glucose monitoring, structural heart interventions, and lab diagnostics—it is one of the clear leaders, competing directly with other global heavyweights. Its long history, trusted brand, global distribution, and large installed base of equipment make it hard for smaller rivals to displace. That said, it still faces intense competition from well-funded peers, pricing pressure from payers, and ongoing regulatory scrutiny in all major markets.

Innovation and R&D

Innovation and R&D Innovation is at the core of Abbott’s strategy. The company has built strong positions in technologies like the FreeStyle Libre glucose sensors, Alinity lab systems, portable i‑STAT diagnostics, and minimally invasive heart devices such as MitraClip, TriClip, and leadless pacemakers. It continues to extend its sensor expertise into consumer health with the Lingo biowearables concept, aiming to tap into the broader wellness and performance market. The push into point‑of‑care testing for brain injury and the planned move deeper into cancer diagnostics through the Exact Sciences deal show a willingness to enter new, high‑growth areas. These initiatives offer substantial long‑term opportunity but depend on successful product execution, regulatory approvals, integration of acquisitions, and market adoption, all of which carry meaningful uncertainty.

Summary

Abbott looks like a financially solid, cash‑generative healthcare company with a long operating history and a broad, diversified portfolio. Its earnings profile has been influenced by temporary pandemic testing demand and some one‑time items, but underlying profitability and cash flow appear steady and resilient. The balance sheet is strengthening as debt comes down and equity builds, providing room to keep investing in growth. Competitively, Abbott benefits from scale, brand, and a wide footprint across devices, diagnostics, and nutrition, though it must constantly defend share against other global leaders. Its innovation engine—spanning glucose monitoring, structural heart, diagnostics, and emerging consumer biowearables—creates significant growth potential, but also brings the usual risks around regulation, competition, reimbursement, and execution. Overall, the data depict a mature healthcare leader using strong finances to support a broad pipeline of future growth projects, with outcomes that will depend heavily on how well those innovations are delivered and adopted.

NEWS

November 21, 2025 · 8:30 PM UTC

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

Read more

November 20, 2025 · 7:30 AM UTC

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

Read more

October 30, 2025 · 1:00 PM UTC

Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV

Read more

October 15, 2025 · 7:30 AM UTC

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

Read more

October 6, 2025 · 8:00 AM UTC

Ventric Health Appoints Managed Care Veteran Christopher Abbott to Board of Directors

Read more